{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sintilimab"]],"indication":"resectable locally advanced NSCLC harboring no driver mutations","name":"NCT05157776","nct_id":"NCT05157776","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05157776. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Neoadjuvant therapy of Sintilimab and chemotherapy in 2 cycles before surgery and optional adjuvant therapy of Sintilimab and chemotherapy in 2 cycles after surgery","label":"Control group","type":"ACTIVE_COMPARATOR"},{"description":"Neoadjuvant therapy of Sintilimab and chemotherapy in 4 cycles before surgery","label":"Experimental group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-10-31","type":"ESTIMATED"},"conditions":["NSCLC, Stage IIIA","EGF-R Negative Non-Small Cell Lung Cancer","ALK Negative NSCLC"],"enrollment":{"count":72,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"PD-1 and chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2023-05-09","lead_sponsor":"Tongji University","official_title":"Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III Trial","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2024-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathologically complete response (pCR) rate","timeFrame":"in three weeks after the surgical resection"}],"references":[{"citation":"Lin D, Wu L, Wang P, Li X, Wang X, Cai Y, Xiong K, Chen X, Yang F, Huang W, Wang X, Fan J. Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients. Front Oncol. 2025 Jul 24;15:1563315. doi: 10.3389/fonc.2025.1563315. eCollection 2025.","pmid":"40777124","type":"DERIVED"}],"start_date":{"date":"2021-10-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","url":"https://clinicaltrials.gov/study/NCT05157776"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05157776"}